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ERp57Myelin oligodendrocyte glycoprotein (MOG) is a type I integralmembraneprotein that is expressed in the central
nervous system.MOGhas a single N-glycosylation sitewithin its extracellular domain.MOGhas been linkedwith
pathogenesis of multiple sclerosis; anti-MOG antibodies have been detected in the sera of multiple sclerosis
patients. N-glycosylation is an important post-translational modiﬁcation of protein that might impact their fold-
ing, localization and function. However, the role of sugar in the biology of MOG is not well understood. In this
study, we created a mutant MOG lacking N-linked glycan and tested its properties. We concluded that the lack
of sugar did not impact on MOG abundance in the absence of endoplasmic reticulum molecular chaperone
calnexin. We also show that the absence of N-glycan did not interfere with MOG's subcellular localization and
it did not result in activation of endoplasmic reticulum stress. This article is part of a Special Issue entitled:
13th European Symposium on Calcium.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Anti-myelin antibodies play a role in the pathogenesis of multiple
sclerosis, a demyelinating disorder of the central nervous system
(CNS) in a subset of patients [1]. Myelin oligodendrocyte glycoprotein
(MOG) is a relatively minor component of the CNS, however, its locali-
zation to the outermost membrane of the myelin layer makes it an
accessible target for pathogenic antibodies [2,3]. MOG has a single gly-
cosylation site within its extracellular domain [4,5], exposed on the sur-
face of the myelin layer, but the physiological and biochemical features
of the MOG glycan remain largely unknown. Post-translational modiﬁ-
cations, including glycosylation, have an important impact on the
antigenic properties of proteins [6]. The role of MOG-glycosylation in
autoantibody binding has been studied using various techniques
[7–9]. Using cell-bound assay it has been shown that the absence of
N-glycan had no signiﬁcant effect on autoantibody binding [7]. Howev-
er, in another studies, NMR analysis show that the presence of glycan on
MOG peptide improves detection by autoantibodies present in the
sera of multiple sclerosis patients, and anti-MOG antibody concentra-
tion corresponds to multiple sclerosis disease severity [10,11]. In therimental autoimmune encepha-
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alak).mouse model pathogenic IgGs, preferentially recognize glycosylated
MOG [9]. Moreover, recently N-glycan on human MOG has been
shown to play a role in immune homeostasis within the CNS [12]. We
have previously shown that calnexin, a molecular chaperone, interacts
with MOG within the lumen of the endoplasmic reticulum (ER) [13],
where the maturation and post-translational modiﬁcations of the
MOG take place. Calnexin and calreticulin are two lectin homolog
chaperones that closely monitor protein folding and maturation in the
lumen of ER; ERp57 is an oxidoreductase that catalysis disulﬁde bond
formation and isomerization in glycoproteins (frequently calnexin/
calreticulin substrates). Together, calnexin, calreticulin and ERp57 are
essential players of the quality control machinery in the lumen of ER
[14]. Here we investigated the effect of a single N-glycosylation site on
MOG cell surface distribution, in a wild-type and chaperones deﬁcient
cells;MOG interactionwith calnexin, induction of ER stress and enceph-
alitogenic properties.
2. Materials and methods
2.1. Cell lines, cell culture, lentiviral transduction and immunoﬂuorescence
Wild-type and calnexin-deﬁcient mouse ﬁbroblasts were isolated
from newborn mice and immortalized [15]. Wild-type and calreticulin-
deﬁcient (K42) mouse embryonic ﬁbroblasts were described previously
[16]. ERp57-deﬁcient mouse embryonic ﬁbroblasts were isolated
from ERp57−/− embryos and immortalized [17]. Lentiviral construct
encoding mouse MOG [13] was used as template to create construct
encodingMOG(N31A)GFP (greenﬂuorescent protein) using site directed
Fig. 1. Expression of MOG(N31A) mutant in wild-type and chaperone deﬁcient cells. A. wt, cnx−/−, ERp57−/− and crt−/− cells were transfected with expression vectors encoding
MOG(N31A)GFP using a lentivirus system. Western blot analysis was carried out with anti-GFP, anti-MOG and anti-GAPDH antibodies. B. Endoglycosidase digestion of MOG–GFP and
P0(N93del)GFP (top panel) used as positive and negative controls, respectively. Lower panel shows endoglycosidase digestion of MOG(N31A)GFP expressed in wild-type (wt) or chaper-
one-deﬁcient cell lines cnx−/−, crt−/− or ERp57−/−. Immunoblots of cell lysates are treatedwith EndoHor PNGaseF. C. Quantiﬁcation of anti-MOGWestern Blots using densitometry, n=2.
D. Flow cytometry analysis of MOG andMOG(N31A) expressing cells. Abbreviations: cnx, calnexin; GFP, green ﬂuorescent protein; crt, calreticulin; GAPDH, glyceraldehyde phosphate de-
hydrogenase; MOG, myelin oligodendrocyte glycoprotein.
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Next, this construct was used to create wild-type, calnexin-deﬁcient
(cnx−/−), calreticulin-deﬁcient (crt−/−) and ERp57-deﬁcient cell lines
stably expressing recombinant MOG(N31A)GFP protein. Cells were
cultured in the presence of 7 μg/ml blasticidine for 14 days [13,18].
Expression of MOG(N31A)GFP protein was monitored by Western blot
analysis using goat anti-GFP (Abcam) or rabbit anti-MOG (Santa-Cruz)
antibodies, or by immunoﬂuorescence, co-staining with ER marker
TexasRed Concanavalin A conjugate using confocal microscopy. For
immunoﬂuorescence, cells expressing MOG–GFP were grown for 24 h
after seeding in culture media on a glass coverslip and ﬁxed in 4% para-
formaldehyde for 12 min. Images were collected by spinning-disk
microscopy (Guelph, Canada) set up on an Olympus IX-81 inverted
stand (Markham, Canada). Images were acquired through a 63× objec-
tive (N.A. 1.42) with an Electron Multiplying Charge Coupled Device
(EMCCD) camera (Hamamatsu, Japan).
2.2. Immunoprecipitation, Western blot and ﬂow cytometry analyses
For immunoprecipitation, cells were grown to 80–90% conﬂuency
followed by the addition of 500 μl/10 cm dish of a lysis buffer con-
taining 50 mM HEPES (pH 7.4), 200 mM NaCl, 2% CHAPS and prote-
ase inhibitors [19]. The samples were incubated on ice for 30 minand then spun at 11,600 ×g for 15 min to remove insoluble material.
Supernatant was pre-cleared with a 1/15th of 10% protein A/G
Sepharose (GE Healthcare Life Science) bead suspension in an HBS
buffer containing 50 mM HEPES (pH 7.4) and 200 mM NaCl. Beads
were centrifuged followed by addition of 2 μl of an appropriate
antibody. The samples were incubated overnight at 4 °C with rota-
tion, followed by addition of 100 μl of 10% protein A/G Sepharose in
HBS buffer, and incubated for an additional 4 h. Beads were
centrifuged, washed 3 times with HBS containing 1% CHAPS
(Sigma), one time with HBS, followed by addition of 30 μl of SDS-
PAGE sample buffer [19]. Proteins were separated by SDS-PAGE
(10% acrylamide).
ForWestern blot analysis, cells expressingMOG–GFP orMOG(N31A)
GFP were lysed on ice in RIPA buffer containing for 150 mM NaCl,
50 mM Tris–HCl (pH 7.4), 0.5% Nonidet P-40, 1% deoxycholate, 0.1% so-
dium dodecyl sulphate, and protease inhibitors for 15 min [15,20].
Brains from mice were isolated, crushed in liquid nitrogen, and lysed
in RIPA buffer for 15 min on ice. The following antibodies were used:
goat anti-GFP 1:10,000, rabbit anti-MOG 1:300 (Santa-Cruz, mouse
monoclonal raised against C-terminus of MOG), rabbit anti-calnexin
1:1000 (Enzo Life Sciences), rabbit anti calreticulin 1:300, rabbit anti-
ERp57 1:1000, and rabbit antiglyceraldehyde dehyrodenase (GAPDH)
1:1000. Sera from control or EAE mice were collected and used to
probe Western blots at 1:300 dilution.
AB
Fig. 2. Glycan independent interaction between calnexin and MOG. A. Cell lysates were
collected from wt or cnx−/− cells stably expressing MOG–GFP, MOG(N31A)GFP or GFP
alone, followed by addition of the goat anti-GFP antibodies. Proteins were separated by
SDS-PAGE followed byWestern blot (WB) analysiswith anti-calnexin (anti-CNX) antibod-
ies. A representativeWestern blot of 3 independent experiments is shown. The arrow in-
dicates the location of calnexin (CNX) and the asterisk marks unspeciﬁc band. IP,
immunoprecipitation. B. Immunoblots of brain protein lysates obtained from wt or
calnexin-deﬁcient mice treated with EndoH or PNGaseF; Western blot with anti-MOG
commercial antibodies.
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SOPR (BD Bioscience) ﬂow cytometer. Data were collected from 10,000
cells and analyzed by FlowJo software. Cells expressing wtMOG–GFP
or MOG(N31A)GFP were collected at conﬂuence of 80–90% into 100 μl
of 0.1% formaldehyde in PBS, and incubated for 30minwith the primary
antibody or mice sera at a concentration of 1:50, for some analysis no
antibodies was added. Cells were than washed 3 times with PBS
containing 2% FBS followed by the addition of the secondary antibody
(Alexa 647, Invitrogen). Staining with secondary antibodies alone was
used as a negative control.
2.3. Endoglycosidase digestions and biotinylation
Cellular proteins were extracted with RIPA buffer containing
protease inhibitors; and 20 μg of total protein was incubated with
EndoH or PNGaseF at 37 °C for 3 h according to the manufacturer's
protocols. Digested and undigested samples were separated by
SDS-PAGE (10% acrylamide) followed by Western blot analysis
with rabbit anti-GFP antibodies at 1:10,000.
For biotinylation of surface proteins, cells were placed on ice and
washed three times with ice-cold PBS–Ca2+ Mg2+ buffer (PBS with
0.1 mM CaCl2 and 1 mM MgCl2). Then, 1.25 mg/ml Sulfo-NHS-SS-
biotin (Pierce) in biotinylation buffer (10 mM triethanolamine, 2 mM
CaCl2, 150 mM NaCl [pH 7.5]) was added at 4 °C and incubated for
30 min with gentle agitation. Later, the cells were washed and incubat-
ed with quenching buffer (PBS–Ca2+–Mg2+ and 100 mM glycine) for
20 min with gentle agitation at 4 °C. The cells were then rinsed twice
with PBS, scraped off in ice-cold PBS, and pelleted at 2000 rpm for
5min at 4 °C. The resulting pellets were solubilized in 500 μl lysis buffer
(10% glycerol, 1% Triton X-100, 150 mM NaCl, 5 mM EDTA, 50 mM
Hepes (pH 7.4), with protease inhibitors) for 40–45 min, and the
resulting lysates were centrifuged at 14,000 ×g for 10 min at 4 °C. The
recovered supernatant was incubated overnight at 4 °C with gentlerotation with packed streptavidin-agarose beads (Invitrogen, Carlsbad,
CA, USA), in order to separate the biotinylated proteins. The beads
were then pelleted by centrifugation at 900 rpm for 2 min and aliquots
of supernatants were taken to represent the unbound proteins. Subse-
quently, streptavidin-agarose beads were washed three times with
washing buffer (10% glycerol, 0.1% Triton X-100, 150 mM NaCl,
20 mM HEPES [pH 7.4]). The biotinylated proteins (plasma membrane
proteins) were recovered from the beads by heating them at 100 °C
for 5 min in SDS-PAGE sample buffer. The intracellular protein fractions
and plasma membrane protein fractions were then electrophoresed
separately (but in parallel) and immunoblotted.
2.4. EAE
Nine-week old C57BL/6J mice were randomly selected to be immu-
nized with 100 μg MOG35–55 peptide emulsiﬁed (1:1) in complete
Freund's adjuvant. Pertussis toxin (300 ng, List Laboratories, Campbell,
CA, USA) was injected intraperitoneal on the day of MOG35–55 immuni-
zation and two days later. The remaining three sham mice underwent
the same immunization procedure with incomplete Freund's adjuvant
(without MOG35–55). The mice were assessed daily for neurological dis-
abilities using a standard clinical score. All animal experiments were
carried out according to the University of Alberta Animal Policy and
Welfare Committee and the Canadian Council on Animal Care Guide-
lines. The approval for use of animals in research was granted by the
Animal Care and Use Committee for Health Sciences, a University of
Alberta ethics review committee.
2.5. Unfolded protein response
Unfolded protein responses were measure in wild-type and chaper-
one deﬁcient cells expressingwild-typeMOG (wtMOG) or MOG(N31A).
The luciferase reporter gene assaywas utilized tomeasure ER stress. The
assay utilized an internal Renilla control, the nucleotide sequence of
Xbp1 followed by the ﬁreﬂy luciferase gene [15].
3. Result and discussion
3.1. N-glycosylation mutant of MOG
MOG contains a single N-linked glycosylation site at Asn31 and it is a
powerful antigen for the induction of EAE inmice [21]. Immunization of
mice with MOG35–55 peptide results in the development of experimen-
tal autoimmune encephalomyelitis (EAE), an animal model of multiple
sclerosis [22,23]. The role of MOG's carbohydrate moiety and its contri-
bution to the pathogenesis of MS are unclear. To further investigate the
role of sugar in the biology of MOG, we created a MOG mutant with
substitution of Asn31 for Ala, and expressed this non-glycosylated
MOG in wild-type and chaperone-deﬁcient cells (Fig. 1A).
We further conﬁrmed the absence of N-glycan on MOG(N31A)GFP
with a digestion experiment using the speciﬁc endoglycosidases
EndoH or PNGaseF (Fig. 1B). Digestion with EndoH removes high
mannose N-linked carbohydrates, a characteristic of ER localized glyco-
proteins. Digestion with PNGaseF removes both high mannose and
complex carbohydrates found on Golgi and plasmamembrane localized
proteins. The upper panel of Fig. 1B shows digestion of a positive (glyco-
sylated) control (wtMOG–GFP), and a negative control (P0(N93del)
GFP), fully resistant to digestion by glycosidases. As predicted,
MOG(N31A)GFP expressed in wild-type and chaperone-deﬁcient cells
were strongly resistant to both EndoH and PNGaseF digestion, indicat-
ing the lack of glycan on the mutated protein (Fig. 1B).
Wild-type, cnx−/−, crt−/− and ERp57−/− cells were transfected with
an expression vector encoding MOG(N31A)GFP followed by Western
blot analysis with anti-GFP and anti-MOG antibodies. Fig. 1A shows
that the MOG(N31A)GFP protein has a faster mobility in SDS-PAGE
when compared to the wild-type wtMOG–GFP protein, due to the
BA
Fig. 3. Cell surface targeting of MOG(N31A)GFP in wild-type and chaperone-deﬁcient cells. A. Confocal images of cell surface expression of MOG(N31A)GFP (left panels) in calnexin-deﬁ-
cient (cnx−/−), ERp57-deﬁcient (ERp57−/−), calreticulin-deﬁcient (crt−/−) andwild-type (wt) cells. Concanavalin-A (middle panel)was used as an ERmarker. Right panel showsmerging
of GFP (green) and Concanavalin-A (red) imaging. Scale bar = 17 μm. B. Cell surface biotinylation of MOG–GFP, MOG(N31A)GFP expressed in wild-type (wt), calreticulin (crt−/−),
calnexin- (cnx−/−) and ERp57-deﬁcient (ERp57−/−) cell lines. Western blots were probed with anti-GFP or anti-GAPDH antibodies. T lanes, total cellular extracts; UB lanes, material
not bound to the streptavidin afﬁnity beads; B lanes, streptavidin bound, biotinylated fractions. Abbreviations: GFP, green ﬂuorescent protein; GAPDH, glyceraldehyde phosphate
dehydrogenase.
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Fig. 4. Autoantibodies binding to cell MOG(N31A)GFP. Western blot (WB) analysis of ly-
sates from mouse brain or cells expressing wtMOG–GFP or MOG(N31A)GFP serum form
EAEmice (A), using commercial anti-MOG antibody (Santa-Cruz) (B) or serum for control
mice (C). D. Flow cytometry analysis of cell surface fraction (plasmamembrane localized)
of wtMOG–GFP or MOG(N31A)GFP in wt cells with commercial anti-MOG antibody or
serum form EAE mice.
Fig. 5. ER stress induced splicing of XBP1 mRNA. To measure the unfolded protein re-
sponse triggered by MOG(N31A), wt, cnx−/−, crt−/− or ERp57−/− cells stably expressing
MOG(N31A)GFP were transfected with pRL-XFL vector encoding Renilla luciferase and
ﬁreﬂy luciferase reporter genes. Cells expressing wtMOG–GFP were used as a negative
control for ER stress. Cell extracts were collected and assayed for luciferase activity with
the Dual-Luciferase Assay Kit (Promega) using a luminometer (Berthold-Lumat LB
9501) [10,14]. Relative light units (RLU) were normalized to internal control. Average
values ± standard deviation (SD) (n = 3).
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comparable levels in chaperone-deﬁcient and wild-type cells [24], ex-
pression of the mutant protein lacking the glycan was reduced theabsence of the calnexin (Fig. 1A, C). To further examine expression of
MOG(N31A)GFP we performed ﬂow cytometry analysis (Fig. 1D).
Again we saw reduced expression of mutant MOG(N31A)GFP in the
absence of calnexin. Although not clear at present, the reduced expres-
sion of MOG(N31A)GFP in calnexin-deﬁcient cells might be due to
enhanced proteasomal degradation (ERAD) in the absence of calnexin
[15]. Interestingly, MOG(N31A)GFP was more abundant in crt−/− cells
when compared to the levels in the wild-type cells (Fig. 1A, C), indicat-
ing that expression of MOG(N31A)GFP was sensitive to the presence of
calreticulin.
3.2. MOG interacts with calnexin in a glycosylation independent manner
Wehave previously shown that calnexin interactswithwtMOG [13].
Here we examined if calnexin forms complexes with MOG lacking gly-
cosylation at N31 [MOG(N31A)GFP]. Fig. 2A shows that calnexin formed
immunoprecipitable complexes with MOG(N31A)GFP, indicating that
interaction between calnexin and MOG was glycan independent. Our
results conﬁrm the observation that calnexin can act as a chaperone in
a glycan-independent way [25]. Moreover, since MOG(N31A)GFP pro-
tein is not retained (shown later) in the ER, immunoprecipitation
results of MOG(N31A)GFP and calnexin were not just an effect of accu-
mulation of misfolded protein in the ER.
Calnexin deﬁciency has no effect on MOG expression in the mouse
central nervous system [18]. Here we used EndoH and PNGaseF
endoglycosidases to test the glycosylation state ofMOG in brain samples
collected from calnexin-deﬁcient mice (Fig. 2B). N-glycosylation of
MOG in the brain samples from calnexin-deﬁcient mice was unaltered
when compared to its wild-type littermate (Fig. 2B). Furthermore,
sugarmight not be critical for MOG folding butmay affect the efﬁciency
of folding hence lower level of MOG(N31A) expression in the calnexin-
deﬁcient cells (Fig. 1A, B) while the expression levels of wtMOG in
wild-type vs cnx−/− cells was at comparable levels [13].
3.3. Subcellular localization of the N-glycosylation MOG mutant
Next, we used confocal microscopy to investigate the intracellular
localization of MOG(N31A)GFP in cells deﬁcient in ER quality control
chaperones. The bulk of MOG(N31A)GFP was localized to the plasma
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deﬁcient cells (Fig. 3A) suggesting that the N-glycosylation of MOG
was not essential for cell surface targeting and that the absence of
calnexin, calreticulin and ERp57 did not affect cell surface targeting of
MOG(N31A)GFP.
Cell surface localization of MOG(N31A)GFP was further investigated
using a membrane-impermeant biotin that labels surface proteins
(Fig. 3B). Wild-type and chaperone-deﬁcient cell lines expressing
MOG(N31A)GFP were labeled with sulfo-NHS-biotin followed by isola-
tion of the biotinylated proteins using streptavidin-afﬁnity chromatog-
raphy [26]. Total cellular proteins (T), unbound and streptavidin
bound proteins were separated by SDS-PAGE followed by Western
blot analysis with anti-GFP antibodies to identify in which fraction
MOG(N31A)GFP was present. Western blot analysis of GAPDH, a cyto-
plasmic protein, was used as an internal control indicating the cell sur-
face biotinylating protocol identiﬁed cell surface proteins only. Fig. 3B
shows that biotinylatedMOG(N31A)GFPwas correctly localized to plas-
mamembrane inwild-type and chaperone-deﬁcient cellswas relatively
similar to the cell surface localized wtMOG–GFP.
3.4. Autoantibodies binding to glycosylated vs unglycosylated MOG
MOG plays role in the pathology of MS, a chronic inﬂammatory dis-
ease of theCNS. Interestingly,MOGwasﬁrst identiﬁed as the antigen re-
sponsible for the demyelination observed in animals injected with
whole CNS homogenate [27]. Anti-MOG antibodies have been found
in sera of subset of patients withMS, and their presence is directly asso-
ciated with myelin damage [1,28]. Anti-MOG antibodies are also part of
pathogenesis of EAE an animalmodel that resemblesmany pathological
features of human MS [29]. We used sera from mice immunized with
MOG35–55 peptide — (EAE), and tested for recognition in lysates from
cells deﬁcient in ER chaperones expressing wtMOG–GFP or
MOG(N31A)GFP. Western blot analysis using EAE sera (Fig. 4A) were
consistent with results obtained with the commercial anti-MOG anti-
bodies (Fig. 4B), sera from the control mice were used as a control
(Fig. 4C). However, Western blot analysis provides a measure of total
protein but does not allow to distinguish between antibodies that pref-
erentially recognize intact, correctly folded MOG. Next we utilize cell
based assay (ﬂow cytometry) to address wheatear pathogenic antibody
from EAEmice sera show speciﬁcity to glycan on plasmamembrane lo-
calizedMOG (Fig. 4D). Interestingly, antibodies from the EAEmice pref-
erentially recognized MOG(N31A)GFP to wild-type glycosylated variant
ofMOG. It is possible that theN-glycan on theMOG reduces the interac-
tion with the pathogenic antibodies that were developed against non-
glycosylated peptide. Our ﬁnding is in line with data results of Mayer
et al., which show that antibodies form human MS sera can in some
cases preferentially recognize unglycosylated human MOG [7].
3.5. Endoplasmic reticulum stress in cell expressing mutant MOG
ER stress is usually triggered in response to build up of misfolded
proteins in the lumen of ER [30]. The reason for accumulation of un-
folded proteins can range from protein mutations to changes in the
environment of the lumen of ER [31]. Recently, ER stress has been
linked with the pathology of multiple sclerosis [32]. Consequently,
we tested if the expression of non-glycosylated MOG would induce
ER stress. Surprisingly, expression of glycan deﬁcient MOG did not
induce Xbp-1 splicing (Fig. 5), a marker of unfolded protein re-
sponse, indicating that the absence of glycan did not interfere did
not result in the ER retention of the potentially misfolded protein.
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